)
)
Egetis Therapeutics Investor Relations Material
Latest events
Study Update
Egetis Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Egetis Therapeutics
Access all reports
Egetis Therapeutics develops and markets drugs for the treatment of rare and serious diseases in the orphan drug segment. Its main drug candidates currently include Aladote, a drug that reduces the risk of acute liver injury associated with acetaminophen/paracetamol poisoning and is being developed in phase IIb/III clinical trials; and Emcitate, a drug for the treatment of MCT8 deficiency (a rare inborn error of thyroid hormone signaling).
Key slides for Egetis Therapeutics
Corporate Presentation
Egetis Therapeutics
Corporate Presentation
Egetis Therapeutics
Latest articles
)
James Quincey: Coca-Cola Chairman and CEO
James Quincey has dedicated nearly three decades to The Coca-Cola Company, rising through the ranks to become CEO and Chairman of the company.
11 Mar 2025
)
PepsiCo: From Pepsi and Gatorade to Doritos and Lay's
PepsiCo has grown from a soda company into a global leader in food and beverages, with a portfolio of over 200 brands, including Pepsi, Lay's, and Gatorade.
11 Mar 2025
)
Bob Iger: Disney's Visionary CEO
Bob Iger is a legend in the entertainment industry, known for his visionary leadership and as one of the most influential CEOs in Disney's history.
10 Mar 2025
Ticker symbol
EGTX
Country
🇸🇪 Sweden